Clinical trials: Phase I
Advanced Solid Tumor
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
This is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP3 in adult participants with advanced solid tumors, to evaluate the safety and tolerability of RP3 both as a single…
- Trial name
- NCT04735978
- Testing
- RP3, Nivolumab
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 123 people
- Sponsor
- Replimune, Inc.
Hepatitis C
Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection
The GI-5005 therapeutic vaccine or placebo will be injected under the skin of hepatitis C virus (HCV) subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections.
- Trial name
- NCT00124215
- Testing
- GI-5005
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- GlobeImmune
Neuropathy of Diabetes
Phase I Single-dose Escalation Clinical Trial of Salvianolic Acid A Tablets
Salvianolic acid A has a variety of pharmacological effects, such as: anti-oxidation, scavenging oxygen free radicals, anti-fibrosis, anti-myocardial ischemia, anti-coagulation, anti-thrombosis, anti-tumor, etc.
- Trial name
- NCT03791125
- Testing
- Salvianolic Acid A
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Neoplasms
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
This is the first study where BAY1125976 is given to humans. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme (no placebo group) to determine the safety, tolerability and maximum tolerated…
- Trial name
- NCT01915576
- Testing
- BAY1125976
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 79 people
- Sponsor
- Bayer
Advanced Solid Tumor
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors
This is the first in human study of BL0020, and the primary objective is to evaluate the safety and tolerability, and determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of BL0020 as a single agent in…
- Trial name
- NCT05886868
- Testing
- BL0020
- Where
- 4 sites in Australia, China
- Volunteers
- 66 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
This phase I trial studies the side effects and best dose of veliparib when given together with carboplatin and to see how well they work in treating patients with human epidermal growth factor 2 (HER2)-negative breast cancer…
- Conditions
- Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT01251874
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Healthy
An Open Label Pilot Study to Evaluate the Efficacy of Spanish Black Radish on the Induction of Phase I and Phase II Enzymes
This study will investigate the effect of Spanish Black Radish on phase I and phase II enzyme activity in healthy adult males. The primary objective is to determine the effect on phase I and phase II enzyme activity by measuring…
- Trial name
- 11SEHS (NCT02137590)
- Testing
- Spanish Black Radish product
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Solid Tumor, Adult, Relapsed Cancer
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of…
- Conditions
- Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT05662397
- Testing
- HST-1011, Cemiplimab
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 77 people
- Sponsor
- HotSpot Therapeutics, Inc
Breast Cancer, Breast Neoplasm
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
- Conditions
- Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
- Trial name
- NCT06075810
- Testing
- MBQ-167
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 48 people
- Sponsor
- MBQ Pharma
Malaria, Falciparum
A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants
The primary purpose of the study is to characterise the safety of GSK4024484 in healthy participants within a controlled pharmacokinetic (PK) range, and the effect of food on the study intervention.
- Trial name
- NCT06171113
- Testing
- GSK4024484C
- Where
- United Kingdom
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Solid Tumor
Food-Effect and Metabolism Study in Healthy Subjects
This study evaluates the food-effect of one-dose Fluzoparib in healthy subjects. The participants receive Fluzoparib 120mg in fed state in Period 1 followed by administration of Fluzoparib 120mg in fasted state in Period 2.
- Trial name
- NCT03062982
- Testing
- Fluzoparib
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Sarcoma
BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma
Phase I/II trial to study the effectiveness of BMS-275291 in treating patients who have HIV-related Kaposi's sarcoma. Drugs such as BMS-275291 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.
- Trial name
- NCT00024024
- Testing
- rebimastat
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
To find the recommended dose of TROP2- CAR-NK cells that can be given to participants with advanced forms of solid tumors.
- Trial name
- NCT06066424
- Testing
- Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Helicobacter Pylori Infection
Drug-Drug Interactions Between TNP-2198 and Midazolam, Clarithromycin
This is a single center, open label, drug-drug interaction, Phase 1 study of TNP-2198 in approximately 32 healthy participants, includes 2 cohorts (16 participants per cohort): Midazolam cohort and Clarithromycin cohort.
- Trial name
- NCT06551623
- Testing
- Midazolam, Clarithromycin, TNP-2198
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- TenNor Therapeutics Inc.
Advanced Liver Cancer
OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer
An open-label dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of OH2 injection via transcatheter Intraarterial infusion in patients with advanced hepatocellular carcinoma
- Trial name
- NCT05698459
- Testing
- OH2 injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Skin Neoplasms
Safety Study of a Fluorescent Marker to Visualize Cancer Cells
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed.
- Trial name
- NCT02097875
- Testing
- BLZ-100
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- Blaze Bioscience Australia Pty Ltd
Healthy Subjects
Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in Healthy Volunteers.
Characterize the relative pharmacokinetics (PK) of 3 marketed products containing guaifenesin
- Trial name
- NCT03643575
- Testing
- Vicks Cough Syrup for Chesty Coughs, Robitussin Extra Strength Chest Congestion, Organ-I- NR tablet
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Inc.
Advanced Cancer, Cachexia
A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors
The purpose of this clinical trial is to evaluate the safety and tolerability of SXRN Plasmid DNA Technique in patients with advanced solid tumors.
- Trial name
- NCT06736275
- Testing
- SXRN
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Jiangsu Nutai Biologics Co., Ltd
Hematologic Malignancies
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.
- Trial name
- NCT01476657
- Testing
- IPI-145 (duvelisib)
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- SecuraBio
Hepatic Impairment
Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332
The study is to estimate the effect of hepatic impairment on the plasma PK of PF-07321332/ritonavir. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted…
- Trial name
- NCT05005312
- Testing
- PF-07321332, Ritonavir
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.